Vera Therapeutics (NASDAQ:VERA) Shares Down 7.4% – Should You Sell?

Vera Therapeutics, Inc. (NASDAQ:VERA) shares traded down 7.4% on Monday . The company traded as low as $45.55 and last traded at $45.1160. 538,975 shares traded hands during trading, a decline of 48% from the average session volume of 1,035,229 shares. The stock had previously closed at $48.71.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a research note on Friday, November 28th. Wedbush boosted their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. Bank of America lifted their price target on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.83.

Vera Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company has a market cap of $2.97 billion, a P/E ratio of -11.64 and a beta of 1.16. The stock’s fifty day moving average price is $40.18 and its two-hundred day moving average price is $30.24.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter last year, the business posted ($0.85) EPS. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the transaction, the senior vice president owned 47,839 shares of the company’s stock, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Patrick G. Enright acquired 5,882 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $42.50 per share, with a total value of $249,985.00. Following the purchase, the director owned 5,882 shares in the company, valued at $249,985. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 16.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently modified their holdings of VERA. GAMMA Investing LLC increased its holdings in Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares in the last quarter. Virtus Investment Advisers LLC grew its holdings in shares of Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after purchasing an additional 539 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Vera Therapeutics by 2.0% during the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after purchasing an additional 550 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Vera Therapeutics by 13.3% in the second quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock valued at $124,000 after buying an additional 615 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Vera Therapeutics by 2.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,721 shares of the company’s stock valued at $744,000 after buying an additional 816 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.